Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Drug Device Combination Market?

In recent years, the market size for drug device combinations has experienced substantial growth. It is projected to expand from $131.01 billion in 2024 to $144.22 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The escalated growth observed in the historic period is due to factors such as the surge in medical innovation, the escalation in chronic diseases, the focus on patient-centric approaches, progress in biologics, the complications of monotherapy, and clinical needs.

The market size for drug device combinations is predicted to experience a steep surge in the coming years, ballooning up to $224.68 billion by 2029, with an 11.7% compound annual growth rate (CAGR). The projected growth within this period can be linked to several factors such as increased patient involvement and engagement, digitization of healthcare, worldwide market expansion, the advent of innovative therapies, and value-based healthcare. Major forecast period trends encompass therapeutic breakthroughs, complicated disease management, patient-focused care, technological advancements, and regulatory backing.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8206&type=smp

What Core Drivers Are Expected To Influence The Drug Device Combination Market?

The escalating prevalence of chronic illnesses is predicted to fuel the growth of the drug-device combination market. Chronic illnesses are diseases that last for a year or more, hindering daily activities and requiring ongoing medical attention. These include heart diseases and diabetes among others. Drug-device combinations are diagnostic and therapeutic products which are pivotal in treating individuals with chronic conditions. For instance, a 2022 report from the World Health Organization, an agency of the United Nations devoted to global public health, stated that diabetes affected over 420 million people worldwide. This number is projected to rise to 578 million and 700 million in 2030 and 2045 respectively. Consequently, the growing prevalence of chronic diseases is propelling the expansion of the drug-device combination market.

What Are The Main Segment Classifications In The Drug Device Combination Market?

The drug device combinationmarket covered in this report is segmented –

1) By Product: Auto-Injector, Microneedle Patch, Digital Pill, Smart Inhaler, Drug Delivery Hydrogels, Drug-Eluting Lens, Other Products

2) By Distribution Channel: Direct Tender, Retails Sales, Other Distribution Channels

3) By Application: Orthopedic Diseases, Respiratory Diseases, Diabetes, Oncology, Cardiovascular Diseases, Other Applications

4) By End User: Clinics, Hospitals, Home Care Settings, Ambulatory Care Centers, Other End Users

Subsegments:

1) By Auto-Injector: Pre-Filled Auto-Injectors, Reusable Auto-Injectors

2) By Microneedle Patch: Dissolving Microneedle Patches, Coated Microneedle Patches

3) By Digital Pill: Ingestible Sensors, Smart Capsules

4) By Smart Inhaler: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)

5) By Drug Delivery Hydrogels: Injectable Hydrogels, Topical Hydrogels

6) By Drug-Eluting Lens: Contact Lenses, Intraocular Lenses

7) By Other Products: Transdermal Patches, Implantable Drug Delivery Systems

How Are Industry Trends Steering The Expansion Of The Drug Device Combination Market?

Mainstream businesses in the drug combination device industry, such as Trelegy Ellipta, are introducing new products to maintain market dominance. The inhaler, Trelegy Ellipta, delivers a precise quantity of medication to the lungs and is the first of its kind to offer triple therapy in a single device. GSK, a pharmaceutical and biotechnology firm based in the UK, launched this handheld, lightweight gadget in April 2022. Its primary application is the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Capable of housing up to three unique drugs in its foil packaging, the Ellipta inhalers are utilized for combination therapy. Trelegy Ellipta merges three active components – fluticasone furoate, umeclidinium, and vilanterol – in a single inhaler, solidifying its role as a drug combination device that improves patient management of respiratory issues with its consolidated delivery system.

Which Companies Are Contributing Significantly To The Drug Device Combination Market Growth?

Major companies operating in the drug device combination market are The 3M Company, Abbott India Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Medtronic PLC, Ypsomed Holding AG, Micron Biomedical Inc., MetP Pharma AG, Sonceboz SA, Lepu Medical Technology (Beijing) Co. Ltd., Eitan Medical Ltd., Vaxess Technologies Inc., Subcuject Aps, Allergan PLC, Terumo Corporation, Stryker Corporation, Becton Dickinson and Company, Zimmer Biomet Holdings Inc., MediPrint Ophthalmics, Arrow International Inc., Alcon Inc., W. L. Gore & Associates Inc., Cook Medical LLC, Pinnacle Biologics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/drug-device-combination-global-market-report

Which Region Holds The Greatest Opportunity For Drug Device Combination Market Expansion?

North America was the largest region in the drug-device combination market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug device combination market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8206&type=smp

Browse Through More Reports Similar to the Global Drug Device Combination Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model